Oct 26, 2026 · 11 min
Brazil election jolts European stocks as Genmab rallies
Telefonica Drops, Galp Falls, Genmab Surges
The episode connects political exposure, a failed energy deal, and clinical-trial news to sharp moves across European markets.
- 1Brazil’s election results weigh on Telefónica, Santander, Carrefour, and other companies with exposure to the country.
- 2Galp Energia’s proposed deal with Moeve collapses, adding a corporate setback to the market roundup.
- 3Genmab surges after positive late-stage ovarian-cancer trial results, while electric-vehicle sales show renewed strength.
Don't miss
Genmab’s surge after positive late-stage ovarian-cancer trial results provides the episode’s clearest example of clinical news moving a stock.
The brief
Brazil’s election results ripple through European equities, hitting Telefónica and other Brazil-exposed companies while Santander and Carrefour also enter the market discussion.
The report then turns from political risk to corporate news: Galp Energia’s proposed deal with Moeve collapses, while Genmab rises on positive late-stage ovarian-cancer trial results.
Beyond the main movers, the episode previews Dubai’s rapid urban growth and the use of artificial intelligence and innovation in planning smarter city infrastructure.
A separate technology report describes SpaceX’s demanding hiring culture, where candidates are expected to show exceptional ability, loyalty, and alignment with company values.
The closing update finds renewed strength in electric vehicles, with Tesla and Rivian beating third-quarter sales expectations and Hyundai and Ford seeing stronger dealer demand.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.